Phenserine

Last updated
Phenserine
Phenserine.svg
Clinical data
Other names(-)-Phenserine, (-)-Eseroline phenylcarbamate, N-phenylcarbamoyleseroline, N-phenylcarbamoyl eseroline
Routes of
administration 		By mouth
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Bioavailability ~100% [1]
Metabolism liver
Metabolites (−)-N1-norphenserine, (−)-N8-norphenserine, (−)-N1,N8-bisnorphenserine
Elimination half-life 12.6 minutes
Duration of action 8.25 hours [2]
Excretion renal or hepatic clearance [2]
Identifiers
  • (3a'S,8aR)-1,3a,8-Trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.162.417 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C20H23N3O2
Molar mass 337.4155 g·mol−1
3D model (JSmol)
Melting point 150 °C (302 °F)
  • [H][C@]12N(C)CC[C@@]1(C)C1=C(C=CC(OC(=O)NC3=CC=CC=C3)=C1)N2C
  • InChI=InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m1/s1
  • Key:PBHFNBQPZCRWQP-QUCCMNQESA-N

Phenserine (also known as (-)-phenserine or (-)-eseroline phenylcarbamate) is a synthetic drug which has been investigated as a medication to treat Alzheimer's disease (AD), as the drug exhibits neuroprotective and neurotrophic effects.

Contents

The research of phenserine, initially patented by the National Institute on Aging (NIA), [3] has been suspended since phase III of clinical trials in 2006, conducted right after the drug licenses were issued. [4] The abandonment of the clinical trials led to disapproval by FDA. [5] The retrospective meta-analysis of the phenserine research proposed that its clinical invalidation was arisen from methodological issues that were not impeccably settled before proceeding to the subsequent clinical phases. [5] [6]

Phenserine was introduced as an inhibitor of acetylcholinesterase (AChE) and demonstrated significant alleviation in numerous neuropathological manifestations, improving cognitive functions of the brain. [7] The ameliorative mechanism involves both cholinergic and non-cholinergic pathways. [8] [9]

The clinical translatable doses of phenserine show relatively high tolerability and rarely manifest severe adverse effects. [10] With respect to overdosing of the drug (20 mg/kg), a few cholinergic adverse effects were reported, including nausea and tremor which are not life-threatening. [11]

An administration form of phenserine, (-)-phenserine tartrate, which exhibits high bioavailability and solubility, is taken by mouth. Phenserine and its metabolites can readily access the brain with high permeability across the blood-brain barrier and sustain to act for a long duration with the relatively short half-life. Posiphen ((+)-phenserine), the enantiomer of (-)-phenserine, is also a potential drug by itself or synergically with (-)-phenserine, to mitigate the progression of neurological diseases, mainly Alzheimer's disease. [3]

History

Phenserine was first investigated as a substitute for physostigmine which failed to satisfy the clinical standards for treating Alzheimer's disease, and developed into more compatible remedy. [3] It was initially invented by Nigel Greig whose laboratory is affiliated with the National Institute on Aging (NIA) under the US National Institutes of Health (NIH) which subsequently released a patent of phenserine as an AChE inhibitor in 1995. [3] [12] During phase I in 2000, the supplementary patent regarding its inhibitory mechanism upon β-amyloid precursor protein (APP) synthesis was added. [5] Following 6 years of phase I and II trials, Axonyx Corporation had licensed [6] phenserine to Daewoong Pharmaceutical [13] and QR Pharma (later adopted new corporation name, Annovis Bio) [14] companies in 2006, which then planned to undertake phase III trial and merchandize the drug. However, the clinical deficits ̶ representatively from a double-blinded, placebo-controlled and 7-month phase III trial which had been conducted on 377 mild to moderate Alzheimer's disease patients across Austria, Croatia, Spain, and UK [5] ̶ were discovered and no significance was exhibited for the drug efficacy. This led to the relinquishment of phenserine development, [5] merely displaying its marketable potential.

Approval status

Phenserine failed in phase III of Alzheimer's disease-aimed clinical trials and there has yet been no promise of the trial resumption since 2006. [5] The methodological problems of trials are frequently speculated as the principal reason for the failure of FDA approval as well as the scarcity of Alzheimer's disease drugs. [6] The underlying complications are generated by an inordinate variance in clinical outcomes and poor determination in optimal dosing. [5] [6]

Intra and inter-site variations were incurred by a lack of baseline evaluation and longitudinal assessment on placebo groups. [6] This produced an inadequate power and, thus, appeared to have insufficient statistical significance. In light of the dose determination, the criteria for human subject engagement was not meticulously established before dosing and the effective dose range was not completely established in phase I and II, yet still persisting to phase III. [5] Compared to other Alzheimer's disease drugs, such as donepenzil, tancrine and metrifonate, the clinical advancement of phenserine involves comparably high compliance in outcome measures and protocol regimentation on methods and the clinical phase transition. [5]

Pharmacological benefits

Phenserine was invented as the Alzheimer's disease-oriented treatment in particular, and also proven to have alleviative effects upon other neurological disorders, Parkinson's disease, [9] dementia and amyotrophic lateral sclerosis. [15] The administration of phenserine within the short delay of the disease onset was shown to diminish the severity of neurodegeneration and accompanying cognitive impairments. [4] Its post-injury intervention at clinical translatable doses has been shown to significantly mitigate various neurodegenerative manifestations, preventing chronic deterioration in cognitive functions. [10] The collective neuropathological cascades in the brain are either naturally occurring or provoked by mild or moderate traumatic brain injuries, [16] such as concussion, diffuse axonal injury, ischemic and hypoxic brain injuries [8] [9] [10] The traumatic brain injuries have been substantially examined and induced to form test groups in phenserine research. [10] [17] They are highly correlated with the onset of neurodegenerative disorders, precipitating cognitive, and behavioral impairments.

Phenserine was proven to mitigate the multiple cascades of neuropathology, triggered by traumatic brain injuries, via both cholinergic and non-cholinergic mechanisms. [8] [9]

Pharmacodynamics (mechanism of action)

Cholinergic mechanism

AChE mechanism of action in the synaptic cleft and how phenserine inhibits the AChE AChE Mechanism of Action and How phenserine inhibits it.png
AChE mechanism of action in the synaptic cleft and how phenserine inhibits the AChE

Phenserine serves as an acetylcholinesterase (AChE) inhibitor which selectively acts on the acetylcholinesterase enzyme. [3] It prevents acetylcholine from being hydrolyzed by the enzyme and enables the neurotransmitter to be further retained at the synaptic clefts. [18] Such mechanism promotes the cholinergic neuronal circuits to be activated and thereby enhances memory and cognition in Alzheimer's subjects. [17]

Non-cholinergic mechanism

b-Amyloid (Ab) plaque formation from b-amyloid precursor protein (APP) Amyloid-plaque formation-big.jpg
β-Amyloid (Aβ) plaque formation from β-amyloid precursor protein (APP)

In clinical trials, phenserine was demonstrated to alleviate neurodegeneration, repressing the programmed neuronal cell death and enhancing the stem cell survival and differentiation. The alleviation can be achieved by increase in levels of neurotrophic BDNF and anti-apoptotic protein, Bcl-2, which subsequently reduces expressions of pro-apoptotic factors, GFAP and activates caspase 3. [4] [8] The treatment also suppresses the levels of Alzheimer's disease-inducing proteins which are β-amyloid precursor protein (APP) [19] and Aβ peptide. [8] [20] The drug interaction with the APP gene mediates the expression of both APP and its following product, Aβ protein. This regulating action reverses the glial cell-favored differentiation and increases the neuronal cell output. [17]

Phenserine also attenuates the neuroinflammation which involves the excessive activation of microglial cells to remove the cellular wastes from injury lesions. The accumulation of the activated glia near the site of brain injury is unnecessarily prolonged, stimulating the oxidative stress. [21] The inflammatory response was significantly weakened with the introduction of phenserine, which was evidenced with discouraged expression of pro-inflammatory markers, IBA 1 and TNF-α. [10] The disrupted integrity of the blood brain barrier by a degrading chemical, MMP-9, leading to neuroinflammation, is restored by phenserine as well. [8]

The alpha-synucleins, the toxic aggregates resulting from the protein misfolding, are highly observed in Parkinson's disease. The drug therapy was proven to neutralize the toxicity of alpha-synucleins via protein translation, alleviating the symptoms of the disease. [9]

Dosage

Clinically, the translatable dose of phenserine was primarily employed within a range of 1 to 5 mg/kg where the unit calibration took account of the body surface area. [4] [8] This standard dose range was generally well tolerated in long term trials [10] by neuronal cell cultures, animal models and humans. Increment in dosing by 10 mg/kg is still tolerated without instigating any physiological implication. [2] The maximal administration of phenserine up to 15 mg/kg was reported in rats. [2]

Overdose

The dose of 20 mg/kg and above are appraised as overdosing in which cholinergic adverse effects ensue.

The symptoms of overdosing includes: [11]

Mild symptoms were notified in clinical trials but no other seriously considerable adverse effects were expressed. [5] Tremor was also noted as one of the dose-limiting actions. [2]

Chemistry

Pharmacokinetics

Oral bioavailability of phenserine was shown to be very high, up to 100%. Its bioavailability was tested by computing the drug's delivery rate across the rat's blood brain barrier. [22] The drug concentration, reached in the brain, is 10-fold higher than plasma levels, [23] verifying phenserine as a brain-permeable AChE inhibitor. [24]

Relative to its short plasma half life of 8 to 12 minutes, phenserine exhibits a long duration of action with the half-life of 8.25 hours in which the hindering effect on AChE is time-dependently faded. With the administration of phenserine, 70% or higher AChE inhibitory action in the blood was observed in preclinical studies and with systemic phenserine administration, the extracellular ACh level in the striatum increased up to three times. [24] Through PET studies and microdialysis, the compound's brain permeability was able to be further elucidated. [25]

Enantiomer (posiphen)

Phenserine.svg
Posiphen.svg
Comparison of the chemical structures of phenserine (left) and posiphen (right)

(-)-Phenserine, generally referred to phenserine, acts as an active enantiomer for the inhibition of acetylcholinesterase (AChE) while posiphen, its alternative enantiomer, was comparably demonstrated as a poor AChE inhibitor. [26]

In the history of posiphen research, several companies were interactively involved. In 2005, an Investigational New Drug (IND) application of posiphen was filed with FDA by TorreyPines Therapeutics while its phase I trial on animal models had been implemented by Axonyx. [27] Axonyx and TorreyPines Therapeutics officially signed for their merger agreement [27] in 2006 and licensed the drug to QR Pharma in 2008. [28] The clinical trials of posiphen against Alzheimer's disease are still underway.

Interactions

Currently, 282 drugs have been reported to make interactions with phenserine. [29] [30]

Current research

A 5-year double blinded, donepezil-controlled clinical study for validation of Alzheimer's disease course modification using phenserine has been undertaken as from 2018, involving 200 patients in the UK and US. The study aims to reduce variation in AD therapeutic response between patients via optimal dose formulation. [4]

Related Research Articles

<span class="mw-page-title-main">Acetylcholine</span> Organic chemical and neurotransmitter

Acetylcholine (ACh) is an organic compound that functions in the brain and body of many types of animals as a neurotransmitter. Its name is derived from its chemical structure: it is an ester of acetic acid and choline. Parts in the body that use or are affected by acetylcholine are referred to as cholinergic.

<span class="mw-page-title-main">Cholinergic</span> Agent which mimics choline

Cholinergic agents are compounds which mimic the action of acetylcholine and/or butyrylcholine. In general, the word "choline" describes the various quaternary ammonium salts containing the N,N,N-trimethylethanolammonium cation. Found in most animal tissues, choline is a primary component of the neurotransmitter acetylcholine and functions with inositol as a basic constituent of lecithin. Choline also prevents fat deposits in the liver and facilitates the movement of fats into cells.

<span class="mw-page-title-main">Donepezil</span> Medication used for dementia

Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.

<span class="mw-page-title-main">Physostigmine</span> Chemical compound

Physostigmine is a highly toxic parasympathomimetic alkaloid, specifically, a reversible cholinesterase inhibitor. It occurs naturally in the Calabar bean and the fruit of the Manchineel tree.

<span class="mw-page-title-main">Galantamine</span> Neurological medication

Galantamine is used for the treatment of cognitive decline in mild to moderate Alzheimer's disease and various other memory impairments. It is an alkaloid extracted from the bulbs and flowers of Galanthus nivalis, Galanthus caucasicus, Galanthus woronowii, and other members of the family Amaryllidaceae, such as Narcissus (daffodil), Leucojum aestivum (snowflake), and Lycoris including Lycoris radiata. It can also be produced synthetically.

<span class="mw-page-title-main">Memantine</span> Medication used to treat moderate-to-severe Alzheimers disease

Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.

<span class="mw-page-title-main">Neuroprotection</span> Relative preservation of neuronal structure and/or function

Neuroprotection refers to the relative preservation of neuronal structure and/or function. In the case of an ongoing insult the relative preservation of neuronal integrity implies a reduction in the rate of neuronal loss over time, which can be expressed as a differential equation. It is a widely explored treatment option for many central nervous system (CNS) disorders including neurodegenerative diseases, stroke, traumatic brain injury, spinal cord injury, and acute management of neurotoxin consumption. Neuroprotection aims to prevent or slow disease progression and secondary injuries by halting or at least slowing the loss of neurons. Despite differences in symptoms or injuries associated with CNS disorders, many of the mechanisms behind neurodegeneration are the same. Common mechanisms of neuronal injury include decreased delivery of oxygen and glucose to the brain, energy failure, increased levels in oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammatory changes, iron accumulation, and protein aggregation. Of these mechanisms, neuroprotective treatments often target oxidative stress and excitotoxicity—both of which are highly associated with CNS disorders. Not only can oxidative stress and excitotoxicity trigger neuron cell death but when combined they have synergistic effects that cause even more degradation than on their own. Thus limiting excitotoxicity and oxidative stress is a very important aspect of neuroprotection. Common neuroprotective treatments are glutamate antagonists and antioxidants, which aim to limit excitotoxicity and oxidative stress respectively.

<span class="mw-page-title-main">Huperzine A</span> Chemical compound

Huperzine A is a naturally occurring sesquiterpene alkaloid compound found in the firmoss Huperzia serrata and in varying quantities in other food Huperzia species, including H. elmeri, H. carinat, and H. aqualupian. Huperzine A has been investigated as a treatment for neurological conditions such as Alzheimer's disease, but a meta-analysis of those studies concluded that they were of poor methodological quality and the findings should be interpreted with caution. Huperzine A inhibits the breakdown of the neurotransmitter acetylcholine by the enzyme acetylcholinesterase. It is commonly available over the counter as a nutrient supplement, and is marketed as a cognitive enhancer for improving memory and concentration.

<span class="mw-page-title-main">Tesofensine</span> Chemical compound

Tesofensine (NS2330) is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.

<span class="mw-page-title-main">Acetylcholinesterase</span> Primary cholinesterase in the body

Acetylcholinesterase (HGNC symbol ACHE; EC 3.1.1.7; systematic name acetylcholine acetylhydrolase), also known as AChE, AChase or acetylhydrolase, is the primary cholinesterase in the body. It is an enzyme that catalyzes the breakdown of acetylcholine and some other choline esters that function as neurotransmitters:

<span class="mw-page-title-main">GTS-21</span> Chemical compound

GTS-21 is an investigational drug that has been studied for its potential therapeutic uses, particularly in the treatment of neurodegenerative diseases and psychiatric disorders.

Solanezumab is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer's disease. The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.

<span class="mw-page-title-main">Acetylcholinesterase inhibitor</span> Drugs that inhibit acetylcholinesterase

Acetylcholinesterase inhibitors (AChEIs) also often called cholinesterase inhibitors, inhibit the enzyme acetylcholinesterase from breaking down the neurotransmitter acetylcholine into choline and acetate, thereby increasing both the level and duration of action of acetylcholine in the central nervous system, autonomic ganglia and neuromuscular junctions, which are rich in acetylcholine receptors. Acetylcholinesterase inhibitors are one of two types of cholinesterase inhibitors; the other being butyryl-cholinesterase inhibitors. Acetylcholinesterase is the primary member of the cholinesterase enzyme family.

<span class="mw-page-title-main">Besipirdine</span> Chemical compound

Besipirdine, an indole-substituted analog of 4-aminopyridine, is a nootropic drug developed for the treatment of Alzheimer's disease (AD).

<span class="mw-page-title-main">Rivastigmine</span> Chemical compound

Rivastigmine is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.

<span class="mw-page-title-main">Cymserine</span> Chemical compound

Cymserine is a drug related to physostigmine, which acts as a reversible cholinesterase inhibitor, with moderate selectivity (15×) for the plasma cholinesterase enzyme butyrylcholinesterase, and relatively weaker inhibition of the better-known acetylcholinesterase enzyme. This gives it a much more specific profile of effects that may be useful for treating Alzheimer's disease without producing side effects such as tremors, lacrimation, and salivation that are seen with the older nonselective cholinesterase inhibitors currently used for this application, such as donepezil. A number of cymserine derivatives have been developed with much greater selectivity for butyrylcholinesterase, and both cymserine and several of its analogues have been tested in animals, and found to increase brain acetylcholine levels and produce nootropic effects, as well as reducing levels of amyloid precursor protein and amyloid beta, which are commonly used biomarkers for the development of Alzheimer's disease.

Methanesulfonyl fluoride (MSF) has long been known to be a potent inhibitor of acetylcholinesterase (AChE), the enzyme that regulates acetylcholine, an important neurotransmitter in both the central and peripheral nervous systems.

Neuroinflammation is inflammation of the nervous tissue. It may be initiated in response to a variety of cues, including infection, traumatic brain injury, toxic metabolites, or autoimmunity. In the central nervous system (CNS), including the brain and spinal cord, microglia are the resident innate immune cells that are activated in response to these cues. The CNS is typically an immunologically privileged site because peripheral immune cells are generally blocked by the blood–brain barrier (BBB), a specialized structure composed of astrocytes and endothelial cells. However, circulating peripheral immune cells may surpass a compromised BBB and encounter neurons and glial cells expressing major histocompatibility complex molecules, perpetuating the immune response. Although the response is initiated to protect the central nervous system from the infectious agent, the effect may be toxic and widespread inflammation as well as further migration of leukocytes through the blood–brain barrier may occur.

Donanemab is a biological drug in Phase III clinical trials to determine whether it slows the progression of early Alzheimer's disease. There is currently no cure or disease-modifying treatment for Alzheimer's disease except for lecanemab. Donanemab has shown positive results in its first trials. Donanemab was developed by the Eli Lilly and Co. and is under clinical development as a possible treatment for Alzheimer’s disease.

<span class="mw-page-title-main">Buntanetap</span> Chemical compound

Buntanetap is an orally-administered small molecule inhibitor of several neurotoxic proteins that is under investigation in the treatment of Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy and Parkinson's disease. It is the (+) enantiomer of phenserine, as the (-) enantiomer also has unwanted anticholinergic effects. It is currently in phase III trials for the treatment of Parkinson's.

References

  1. ↑ Greig NH, De Micheli E, Holloway HW, Yu QS, Utsuki T, Perry TA, et al. (2000-01-02). "The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics". Acta Neurologica Scandinavica. Supplementum. 176 (s176): 74–84. doi: 10.1034/j.1600-0404.2000.00311.x . PMID   11261809. S2CID   25710804.
  2. 1 2 3 4 5 Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, Lahiri DK (July 2005). "An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease". Current Alzheimer Research. 2 (3): 281–90. doi:10.2174/1567205054367829. PMID   15974893.
  3. 1 2 3 4 5 Klein J (July 2007). "Phenserine". Expert Opinion on Investigational Drugs. 16 (7): 1087–97. doi:10.1517/13543784.16.7.1087. PMID   17594192. S2CID   219292296.
  4. 1 2 3 4 5 Becker RE, Greig NH, Lahiri DK, Bledsoe J, Majercik S, Ballard C, et al. (2018). "(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease". Current Alzheimer Research. 15 (9): 883–891. doi:10.2174/1567205015666180110120026. PMC   6039273 . PMID   29318971.
  5. 1 2 3 4 5 6 7 8 9 10 Becker RE, Greig NH (December 2012). "Was phenserine a failure or were investigators mislead by methods?". Current Alzheimer Research. 9 (10): 1174–81. doi:10.2174/156720512804142912. PMC   5182048 . PMID   23227991.
  6. 1 2 3 4 5 Becker RE, Greig NH (November 2010). "Why so few drugs for Alzheimer's disease? Are methods failing drugs?". Current Alzheimer Research. 7 (7): 642–51. doi:10.2174/156720510793499075. PMC   3010269 . PMID   20704560.
  7. ↑ Sharma K (August 2019). "Cholinesterase inhibitors as Alzheimer's therapeutics (Review)". Molecular Medicine Reports. 20 (2): 1479–1487. doi:10.3892/mmr.2019.10374. PMC   6625431 . PMID   31257471.
  8. 1 2 3 4 5 6 7 Luo C, Pan SY (January 2015). "The pathways by which mild hypothermia inhibits neuronal apoptosis following ischemia/reperfusion injury". Neural Regeneration Research. 10 (1): 153–8. doi: 10.4103/1673-5374.150725 . PMC   4357100 . PMID   25788937.
  9. 1 2 3 4 5 Hsueh SC, Lecca D, Greig NH, Wang JY, Selman W, Hoffer BJ, et al. (2019-06-10). "(-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice". Cell Transplantation. 28 (9–10): 1183–1196. doi:10.1177/0963689719854693. PMC   6767878 . PMID   31177840.
  10. 1 2 3 4 5 6 Greig NH, Lecca D, Hsueh SC, Nogueras-Ortiz C, Kapogiannis D, Tweedie D, et al. (June 2020). "(-)-Phenserine tartrate (PhenT) as a treatment for traumatic brain injury". CNS Neuroscience & Therapeutics. 26 (6): 636–649. doi:10.1111/cns.13274. PMC   7248544 . PMID   31828969.
  11. 1 2 Sugaya K (2015-04-08). "A method of biasing implanted human neural stem cells away from differentiation into glial cells by (+) phenserine to modulate the concentration of soluble ßapp in tissue or csf". Ucf Patents.
  12. ↑ Thatte U (July 2005). "Phenserine Axonyx". Current Opinion in Investigational Drugs. 6 (7): 729–39. PMID   16044670.
  13. ↑ "Axonyx Announces License of Phenserine to Daewoong Pharmaceutical Company for South Korea". www.businesswire.com. 2006-01-04. Retrieved 2020-04-06.
  14. ↑ "Phenserine - Next Generation AChE Inhibitor". Clinical Trials Arena. Retrieved 2020-04-06.
  15. ↑ Becker RE, Kapogiannis D, Greig NH (April 2018). "Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?". Alzheimer's & Dementia. 14 (4): 431–443. doi:10.1016/j.jalz.2017.11.007. PMC   5958613 . PMID   29245000.
  16. ↑ Lecca D, Bader M, Tweedie D, Hoffman AF, Jung YJ, Hsueh SC, et al. (October 2019). "(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice". Neurobiology of Disease. 130: 104528. doi:10.1016/j.nbd.2019.104528. PMC   6716152 . PMID   31295555.
  17. 1 2 3 Hoffer BJ, Pick CG, Hoffer ME, Becker RE, Chiang YH, Greig NH (September 2017). "Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine". Journal of Biomedical Science. 24 (1): 71. doi: 10.1186/s12929-017-0377-1 . PMC   5591517 . PMID   28886718.
  18. ↑ Stanciu GD, Luca A, Rusu RN, Bild V, Beschea Chiriac SI, Solcan C, et al. (December 2019). "Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement". Biomolecules. 10 (1): 40. doi: 10.3390/biom10010040 . PMC   7022522 . PMID   31888102.
  19. ↑ Rizvi SI, Çakatay U (2018-11-02). Molecular Basis and Emerging Strategies for Anti-aging Interventions. Springer. ISBN   978-981-13-1699-9.
  20. ↑ Jain KK (2011-02-14). The Handbook of Neuroprotection. Springer Science & Business Media. ISBN   978-1-61779-049-2.
  21. ↑ Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F (April 2018). "Oxidative stress and the amyloid beta peptide in Alzheimer's disease". Redox Biology. 14: 450–464. doi:10.1016/j.redox.2017.10.014. PMC   5680523 . PMID   29080524.
  22. ↑ Bruinsma G, Cullen E, Greig NH, Lahiri D, Sambamurti K, Friedhoff L (2006-07-01). "P1-004: Oral treatment of mice with Posiphen™ significantly lowers brain levels of beta amyloid (1-42)". Alzheimer's & Dementia. 2 (3S_Part_4): S95. doi:10.1016/j.jalz.2006.05.379. ISSN   1552-5260. S2CID   54399849.
  23. ↑ Becker, Robert E, Author. (6 December 2012). Alzheimer Disease : From Molecular Biology to Therapy. Springer. ISBN   978-1-4612-4116-4. OCLC   1058877507.{{cite book}}: |last= has generic name (help)CS1 maint: multiple names: authors list (link)
  24. 1 2 Skaddan MB, Kilbourn MR, Snyder SE, Sherman PS (February 2001). "Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors". Journal of Cerebral Blood Flow and Metabolism. 21 (2): 144–8. doi: 10.1097/00004647-200102000-00005 . PMID   11176279. S2CID   7644319.
  25. ↑ Skaddan MB, Jewett DM, Sherman PS, Kilbourn MR (July 2002). "(R)-N-[11C]methyl-3-pyrrolidyl benzilate, a high-affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor". Synapse. 45 (1): 31–7. doi:10.1002/syn.10079. hdl: 2027.42/34995 . PMID   12112411. S2CID   9328758.
  26. ↑ Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH (2011-01-07). "Phenserine efficacy in Alzheimer's disease". Journal of Alzheimer's Disease. 22 (4): 1201–8. doi:10.3233/jad-2010-101311. PMC   5161452 . PMID   20930279.
  27. 1 2 "Axonyx and TorreyPines Therapeutics Announce Merger Agreement; Transaction Creates Robust Portfolio in the CNS Disease Area". www.businesswire.com. 2006-06-08. Retrieved 2020-04-08.
  28. ↑ "TorreyPines Therapeutics licenses Posiphen, bisnorcymcerine, phenserine to QR Pharma - Quick Facts". RTTNews. Retrieved 2020-04-08.
  29. ↑ "Phenserine". www.drugbank.ca. Retrieved 2020-04-27.
  30. ↑ Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. (January 2018). "DrugBank 5.0: a major update to the DrugBank database for 2018". Nucleic Acids Research. 46 (D1): D1074–D1082. doi:10.1093/nar/gkx1037. PMC   5753335 . PMID   29126136.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.